Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
Status:
Completed
Trial end date:
2021-06-29
Target enrollment:
Participant gender:
Summary
The primary objective of this research is to evaluate response to systemic therapy, including
anti-angiogenesis therapy and/or immune-based therapies via 18F-DCFPyL prostate-specific
membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) in
patients with metastatic renal cell carcinoma (RCC) and to compare qualitatively with
conventional imaging response criteria - Response Evaluation Criteria In Solid Tumors (RECIST
1.1) and histopathological endpoints including isolation, enumeration and staining of
Circulating Tumor Cells (CTC).
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)